DALLAS, Nov. 7, 2024 /PRNewswire/ — Nanoscope Therapeutics Inc., a late-stage scientific biotechnology firm growing gene therapies for inherited retinal ailments and age-related macular degenerations (AMD), immediately introduced that Sunil Gupta, MD, has joined the Firm’s Board of Administrators. Dr. Gupta is a nationally acknowledged retinal surgeon and a profitable entrepreneur who brings deep expertise in all phases of drug growth and medical gadgets, together with commercialization and manufacturing.
“Dr. Gupta possesses a rare mixture of medical and entrepreneurial experience across the therapy of inherited retinal ailments and dry age-related macular degeneration. He’s a famend, patient-focused doctor, in addition to an efficient chief in executing scientific trials and operations. Dr. Gupta has really superior look after retina sufferers internationally. He might be a useful member of Nanoscope’s board as we advance in direction of commercialization of our mutation-agnostic therapies to revive imaginative and prescient in thousands and thousands of individuals blinded by retinal ailments and dry-AMD,” stated Sulagna Bhattacharya, Co-Founder and Chief Government Officer of Nanoscope.
“Nanoscope continues to advance work on its groundbreaking gene therapies for inherited retinal ailments corresponding to retinitis pigmentosa (RP) and Stargardt, providing hope to sufferers for whom no treatment presently exists,” stated Dr. Gupta. “The corporate’s current bulletins highlighting the efficacy and security outcomes from its randomized Section 2b trial in RP with subsequent BLA submission are revolutionary. With a Section 3 registrational trial for Stargardt and a BLA submitting in RP on the horizon, Nanoscope is nearer to serving to deal with severe unmet wants. Nanoscope has assembled a world-class group of scientists, physicians and enterprise leaders, and I’m excited to contribute.”
“I need to lengthen a heat welcome to Dr. Gupta and look ahead to working with him. He joins us at a pivotal second in Nanoscope’s journey,” stated Glenn Sblendorio, Chairman of the Board. “With an enhanced regulatory pathway, we stay up for using his strategic experience in addition to his community with the retinal neighborhood.”
Dr. Gupta is founder and scientific principal investigator at Retina Specialty Institute (RSI), one of many largest retinal analysis organizations in the USA serving sufferers in clinics throughout the south. He was additionally the founder and chief medical officer of USRetina—one of many largest associations of retina physicians in the USA specializing in drug distribution, GPO, and scientific operational processes and software program growth previous to its current exit to McKesson. He based and serves as chairman and chief medical officer of Clever Retinal Imaging Methods (IRIS), an FDA-cleared, cloud primarily based, telemedicine platform for evaluation of retinal eye illness within the main care setting. Dr. Gupta’s IRIS group is working to finish preventable blindness attributable to diabetic retinopathy and different situations around the globe. Dr. Gupta was the previous chairman of the Andrews Institute Sports activities Medication Middle and served on the board of the Andrews Analysis & Schooling Institute. In these efforts and past, he bridges trade and scientific care supply organizations to optimize affected person expertise and outcomes. Dr. Gupta earned his medical diploma from the College of Cincinnati School of Medication and accomplished his residency in Ophthalmology on the Cullen Eye Institute at Baylor School of Medication in Houston, Texas. He accomplished a Fellowship in Vitreoretinal Illnesses & Surgical procedure on the College of Iowa.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is growing gene-agnostic, sight-restoring optogenetic therapies for the thousands and thousands of sufferers blinded by retinal degenerative ailments, for which no treatment exists. The corporate’s lead asset, MCO-010, just lately reported topline outcomes from the RESTORE Section 2b multicenter, randomized, double-masked, sham-controlled scientific trial within the U.S. for retinitis pigmentosa (NCT04945772). The corporate has accomplished the Section 2 STARLIGHT trial of MCO-010 remedy in Stargardt sufferers (NCT05417126) and just lately introduced plans to provoke a Section 3 registrational trial in Q1 2025. MCO-010 has obtained FDA Quick Monitor designations and FDA orphan drug designations for each retinitis pigmentosa and Stargardt. Preclinical belongings embrace non-viral laser-delivered MCO-020 gene remedy for geographic atrophy.
Investor Contact:
Argot Companions
(212) 600-1902
PR@nanostherapeutics.com
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors-302296855.html
SOURCE Nanoscope Therapeutics
